Elsevier

Biochemical Pharmacology

Volume 34, Issue 16, 15 August 1985, Pages 2975-2982
Biochemical Pharmacology

Activation of tyrosine hydroxylase in the central nervous system by anaerobiosis

https://doi.org/10.1016/0006-2952(85)90024-3Get rights and content

Abstract

Subjecting either P2 fraction or purified synaptosomes isolated from rat brain to periods of anoxic incubation at 30° resulted in activation of dopamine synthesis from tyrosine. This activation was approximately 2.5-fold when the anoxic incubation was carried out at pH 6.2 but was not significant when the pH was 7.4. Measurements of the tyrosine hydroxylase activity at pH 6.2 in Triton X-100-treated preparations of the P2 fraction showed that, after 20 min of anaerobiosis, the Km for pterine cofactor decreased by 39% and the Ki for dopamine increased by 44%; there was no change in the Km for tyrosine. Half-maximal activation of dopamine synthesis occurred in 10 min of anaerobic incubation, and the reversal upon addition of oxygen had a half-time of 15 min. Addition of forskolin or dibutyryl cyclic AMP to anaerobic incubations of P2 fraction did not result in significant activation of dopamine synthesis. Either the removal of calcium or the addition of calmodulin inhibitor, trifluoperazine, substantially decreased the activation of dopamine synthesis induced by periods of anaerobiosis. It appears that during anoxic incubation tyrosine hydroxylase underwent an activation which occurred over a period of minutes, was stable to detergent treatment, and was fully reversed over a period of minutes following reoxygenation. This activation was, at least in part, dependent on the presence of calcium and was sensitive to the calmodulin antagonist trifluoperazine.

References (47)

  • T. Nagatsu et al.

    J. biol. Chem.

    (1964)
  • J.T. Coyle

    Biochem. Pharmac.

    (1972)
  • M. Levitt et al.

    J. Pharmac. exp. Ther.

    (1965)
  • J.M. Masserano et al.

    Molec. cell. biochem.

    (1983)
  • R. Gordon et al.

    J. Pharmac. exp. Ther.

    (1966)
  • H. Thoenen et al.

    J. Pharmac. exp. Ther.

    (1969)
  • R.A. Mueller et al.

    J. Pharmac. exp. Ther.

    (1969)
  • A. Guidotti et al.

    Life Sci.

    (1978)
  • T. Lloyd et al.

    Biochem. biophys. Res. Commun.

    (1974)
  • R.T. Kuczenski et al.

    J. biol. Chem.

    (1972)
  • M. Ikeda et al.

    J. biol. Chem.

    (1966)
  • R.L. Patrick et al.

    J. Neurochem.

    (1974)
  • J.E. Harris et al.

    Nature, Lond.

    (1974)
  • W. Lovenberg et al.
  • R.H. Roth et al.

    Naunyn-Schmiedeberg's Archs Pharmac.

    (1975)
  • M. Goldstein et al.

    Brain Res.

    (1976)
  • R.L. Patrick et al.

    J. Pharmac. exp. Ther.

    (1976)
  • M.M. Ames et al.

    J. biol. Chem.

    (1978)
  • R.J. Pollock et al.

    J. Neurochem.

    (1981)
  • M.A. Lazar et al.

    J. Neurochem.

    (1982)
  • J.D. Raese et al.

    Commun. Psychopharmac.

    (1979)
  • D.W. Andrews et al.
  • S. El Mestikawy et al.

    Nature, Lond.

    (1983)
  • Cited by (7)

    • Chairman's summary of session D

      1986, Biochemical Pharmacology
    View all citing articles on Scopus

    Supported by Grant NS 14505 from the National Institutes of Health.

    On leave of absence from: Medical Research Centre, Polish Academy of Sciences, 3 Dworkowa Str., Warsaw, Poland.

    View full text